Advanced search
Publication Cover
Pathology Volume 33, 2001 - Issue 4
Submit an article Journal homepage
3
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Dendritic Cells and Their Emerging Clinical Applications

Derek Hart Director, Mater Medical Research Institute, South Brisbane, Qld, Australia
Pages 479-492 | Published online: 06 Jul 2009

  • Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. Morphology, quantitation; tissue distribution. J Exp Med 1973; 137: 1142.
  • Hart DNJ, Fabre JW. Demonstration and characterization of lapositive dendritic cells in the interstitial connective tissues of rat heart and other tissues, not brain. J Exp Med 1981; 154: 347-61.
  • Hart DNJ, Fuggle SV, Williams KA, Fabre JW, Ting A, Morris PJ. Localization of HLA-ABC and DR antigens in human kidney. Transplantation 1981; 31: 428-33.
  • McKenzie JL, Beard MEJ, Hart DNJ. Effective depletion of donor dendritic cells prolongs rat cardiac allograft survival. Transplantation 1984; 38: 371-6.
  • Schuler G, Steinman RM. Murine epidermal Langerhans cells mature into potent allostimulatory dendritic cells in vitra J Exp Med 1985; 161: 526-46.
  • Hart DNJ. Dendritic cells: unique leucocyte populations which control the primary immune response. Blood 1997; 90:3245-87.
  • Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
  • Hart DNJ, Clark GJ, MacDonald K, et al. 7th leucocyte differentiation antigen workshop DC section summary. In: Mason D, ed. Leucocyte Typing VU. Oxford: Oxford University Press (in press).
  • Robinson S, Patterson S, English N, Davies S, Knight S, Reid C. Human peripheral blood contains two distinct lineages of dendritic cells. Eur J Immunol 1999; 29: 2769-78.
  • CeIIa M, Jarrossay D, Facchietti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999; 8: 919-29.
  • Ito T, Amakawa R, Inaba M, Ikehara S, Inaba K, Fukuhara S. Differential regulation of human blood dendritic cell subsets by IFNs. J Immunol 2001; 166: 2961-9.
  • McLellan AD, Heiser A, Sorg RV, Fearnley DB, Hart DNJ. Dermal dendritic cells associated with T lymphocytes in normal human skin display an activated phenotype. J Invest Dermatol 1998; 111: 841-9.
  • Strobl H, Riedl E, Scheinecker C, et al. TGF-ßl promotes in vitro development of dendritic cells from CD34* hemopoietic progenitors. J Immunol. 1996; 157: 1499-507.
  • Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumour necrosis factor-a. J Exp Med 1994; 179: 1109-18.
  • Randolph GJ, Inaba K, Robbiani DF, Steinman RM, Muller WA. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 1999; 11: 753-61.
  • Ho CK, Lopez JA, Vuckovic S, Pyke C, Hockey RL, Hart DNJ. Surgical and physical stress increases circulating blood dendritic cell counts independently of monocyte counts. Blood 2001; 98: 145.
  • Summers KL, Hock BD, McKenzie JLA, Hart DNJ. Phenotypic characterisation of five dendritic cell subsets in human tonsils. Am J Pathol 2001; 159:285-95.
  • Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein gp96. Nat Immunol 2000; 1: 151-5.
  • Clark GJ, Angel N, Kato M, et al. The role of dendritic cells in the innate immune system. Microbes Infect 2000; 2: 257-72.
  • Kadowaki N, Antonenko S, Liu YJ. Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c(-) type 2 dendritic cell precursors and CD11c(+ ) dendritic cells to produce type 1 IFN. J Immunol 2001; 166: 2291-5.
  • Sallusto F, Lanzavecchia A. Mobilizing dendritic cells for tolerance, priming and chronic inflammation. J Exp Med 1999; 189: 611-4.
  • Adema GJ, Hartgers F, Verstraten R, et al. A dendritic-cell-derived C-C chemokine that preferentially attracts naive T cells. Nature 1997; 387: 713-5.
  • Vuckovic S, Khalil D, Angel N, et al. Blood plasmocytoid dendritic cells mature with cytokines into CD 123 + CMRF58+ dendritic cells. J Immunol (in press).
  • Egner W, Hart DNJ. The phenotype of freshly isolated and cultured human bone marrow allostimulatory cells: possible heterogeneity in bone marrow dendritic cell populations. Immunology 1995; 85: 611-20.
  • Reid CD, Fryer PR, Clifford C, Kirk A, Tikerpae J, Knight SC. Identification of haemopoietic progenitors of macrophages and dendritic Langerhans cells (DL-CFU) in human bone marrow and peripheral blood. Blood 1990; 76: 1139-49.
  • Blora B, Ho S, Antonenko S, Liu YJ. Generation of interferon alphaproducing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells. J Exp Med 2000; 192: 1785-96.
  • Inaba K, Inaba M, Romani N, et al Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with GM-CSF. J Exp Med 1992; 176: 1693-702.
  • Pulendran B, Banchereau J, Burkeholder S, et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 2000; 165: 566-72.
  • Maraskovsky E, Daro E, Roux E, et al. In vivo generation of human dendritic cell subsets by flu ligand. Blood 2000; 96: 878-84.
  • Zhou L, Schwarting R, Smith HM, Tedder TF. A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. J Immunol 1992; 149: 735-42.
  • Fearnley DB, McLellan AD, Mannering SI, Hock BD, Hart DNJ. Isolation of human blood dendritic cells using the CMRF44 monoclonal antibody: implications for studies on antigen presenting cell function and immunotherapy. Blood 1997; 89: 3708-16.
  • Hock BD, Fearnley DB, Boyce A, et al. Human dendritic cells express a 95kDa activation/differentiation antigen defined by CMRF56. Tissue Antigens 1999; 53: 320-34.
  • Dzionek A, Fuchs A, Schmidt P, et al BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000; 165: 6037-46.
  • Kato M, Nell TK, Fearnley DB, McLellan AD, Vuckovic S, Hart DN. Expression of multilectin receptors and comparative FITC-dextran uptake by human dendritic cells, lnt Immunol 2000; 12: 1511-9.
  • Valladeau J, Ravel O, Dezutter-Dambuyant C, et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity 2000; 12: 71-81.
  • Ariizumi K, Shen GL, Shikano S, et al Cloning of a second dendritic cell-associated C-type lectin (dectin-2) and its alternatively spliced isoforms. J Biol Chem 2000; 275: 11957-63.
  • Geijtenbeek TB, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000; 100: 587-97.
  • Mosialos G, Birkenbach M, Ayehunie S, et al. Circulating human dendritic cells differentially express high levels of a 55-kd actinbundling protein. Am J Pathol 1996; 148: 593-600.
  • de Saint-Vis B, Vincent J, Vandenabeele S, et al A novel lysosomeassociated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is trnsiently expressed in MHC Class II compartment. Immunity 1998; 9: 325-36.
  • Dekker JW, Budhia S, Clark GJ, Hart DNJ, Kato M. Identification of a S-adenosylhomocysteine hydrolase-like transcript induced during dendritic cell differentiation, lmmunogenetics (in press).
  • Clark GJ, Gunrangham SP, Troy AJ, Vuckovic S, Hart DNJ. Expression of the RelB transcription factor correlates with the activation of human dendritic cells. Immunology 1999; 98: 189-96.
  • Miga AJ, Masters SR, Durell BG, et al Dendritic cell longevity and T cell persistence is controlled by CD 154- CD40 interactions. Ear J Immunol 2001; 31: 959-65.
  • Starling GC, McLellan AD, Egner W, Fawcett J, Simmons DL, Hart DNJ. Intercellular adhesion molecule-3 is a costimulatory ligand for LFA-I expressed on human blood dendritic cells. Ear J Immunol 1995; 25: 2528-32.
  • McLellan AD, Starling GC, Williams LA, Hock BD, Hart DNJ. Activation of human peripheral blood dendritic cells induces the CD86 costimulatory molecule. Eur J Immunol 1995; 25: 2064-8.
  • Sorg RV, McLellan AD, Hock BD, Fearnley DB, Hart DNJ. Human dendritic cells express functional interleukin-7. Immunobiology 1998; 198: 26-38.
  • Rissoan M, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999; 283: 1183-6.
  • Heufler C, Koch F, Stanzl U, et al Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-gamma production by T helper 1 cells. Eur J Immunol 1996; 26: 659-68.
  • Kalinski P, Schuitemaker J, Hilkens C, Wierenga E, Kapsenberg M. Final maturation of dendritic cells is associated with impaired responsiveness in IFN-y and to bacterial IL-12 inducers: dendritic ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. J Immunol 1999; 162: 3231-6.
  • Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic T-cell responses is mediated by CD40 signalling. Nature 1998; 393: 478-80.
  • Knight SC, Ipball S, Roberts MS, Macatonia S, Bedford PA. Transfer of antigen between dendritic cells in the stimulation of primary T cell proliferation. Eur J Immunol 1998; 28: 1636-44.
  • den Haan JM, Lehar SM, Sevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. / Exp Med 2000; 192: 1685-96.
  • Fearnley DB, Whyte LF, Carnoutsos SA, Cook AH, Hart DN. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood 1999; 93: 728-36.
  • Vuckovic S, Fearnley DB, Gunrangham SP, Spearing RL, Patton WN, Hart DNJ. Dendritic cells in chronic myelomonocytic leukaemia. Br J Haematol 1999; 105: 974-85.
  • Vuckovic S, Florin THJ, Khalil D, et al CD40 and CD86 upregulation with divergent CMRF-44 expression on blood dendritic cells in inflammatory bowel diseases. Am J Gastroenterol (in press).
  • Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997; 3: 483-90.
  • Brown RD, Pope B, Murray A, et al Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to upregulate CD80 (B7-1) expression after huCD40LT stimulation due to inhibition by TGF-beta 1 and IL-10. Blood (in press).
  • Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-90.
  • Gabrilovich DI, Chen HL, Girgis KR, et al Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Mod 1996; 2: 1096.
  • Bell D, Chomarat P, Broyles D, et al In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999; 190: 1417-25.
  • Coventry BJ. CD1a positive putative tumour infiltrating dendritic cells in human breast cancer. Anticancer Res 1999; 19: 3183-7.
  • Troy AJ, Summers KL, Davidson PJT, Atkinson CA, Hart DNJ. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998; 4: 585-93.
  • Troy AJ, Davidson P, Atkinson C, Hart D. Phenotypic characterization of the dendritic cell infiltrate in prostate cancer. J Urol 1998; 160: 214-9.
  • Troy AJ, Davidson PJT, Atkinson CH, Hart DNJ. CD1a dendritic cells predominate in transitional cell carcinoma of bladder and kidney but are minimally activated. J Urot 1999; 161: 1962-7.
  • Schreiner TU, Lischka G, Schaumburg-Lever G. Langerhans' cells in skin tumors. Arch Dermatol 1995; 131: 187-90.
  • Garcia-Plata D, Lessana-Leibowitch M, Palangie A, et al. Immunophenotype analysis of dendritic cells and lymphocytes associated with cutaneous malignant melanomas. Invasion Metastasis 1995; 15: 125-34.
  • Tcriyama K, Wen DR, Paul E, Cochran AJ. Variations in the distribution, frequency, and phenotype of Langerhans cells during the evolution of malignant melanoma of the skin. J Invest Dermatol 1993; 100: 269S-73S.
  • Lee PP, Yee C, Savage PA, et al Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5:677-85.
  • Dhodapkar MV, Young JW, Chapman PB, et al Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. Clin Cancer Res 2000; 6: 4831-8.
  • Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000; 164: 1269-76.
  • Remmel E, Terracciano L, Noppen C, et al Modulation of dendritic cell phenotype and mobility by tumor cells in vitra Hum Immunol 2001; 62: 39-49.
  • Pardoll DM. Cancer vaccines. Nat Med 1998; 4 (Suppl 5): 525-31.
  • Condon C, Watkins SC, Celluzzi CM, Thompson K, FaIo LD. DNA-based immunization by in vivo transfection of dendritic cells. Nat Med 1996; 2: 1122-8.
  • Roth MD, Gitlitz BJ, Kiertscher SM, et al. Granulccyte macrophage colony-stimulating factor and interleukin 4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res 2000; 60: 1934-41.
  • Janik JE, Miller LL, Kopp WC, et al Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients. Clin Immunol 1999; 93: 209-21.
  • Bernhard H, Disis ML, Heimfeld S, Hand S, Gralow JR, Cheever MA. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells in the bone marrow and peripheral blood. Cancer Res 1995; 55: 1099-104.
  • Thomas R, Chambers M, Boytar R, et al Immature human monocyte-derived dendritic cells migrate rapidly to draining lymph nodes after intradermal injection for melanoma immunotherapy. Melanoma Res 1999; 9:474-81.
  • Barratt-Boyes SM, Watkins SC, Finn OJ. In vivo migration of dendritic cells differentiated in vitro. J Immunol 1997; 158: 4543-7.
  • Romani N, Reider D, Heuer M, et al Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicabililty. J Immunol Methods 1996; 196: 137-51.
  • Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest 2000; 105: R9-14.
  • Dhodapkar MV, Steinman RM, Krasovsky J, Munz M, Bhardwaj N. Antigen-specific inhabition of effector T cell function in humans after injection of immature dendritic cells. J. Exp Med 2001; 193: 233-8.
  • Hart DNJ, Hill GR. Dendritic cell immunotherapy for cancer: application to low-grade lymphoma and multiple myeloma. Immunol Cell Biol 1999; 77:451-9.
  • Mannering SI, McKenzie JL, Hart DNJ. Optimisation of the conditions for generating human DC initiated primary antigen specific T lymphocyte lines in vitro. J Immunol Methods 1998; 219: 69-83.
  • Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52-7.
  • Bendandi M, Gocke CD, Kobrin CB, et al Complete molecular remissions induced by patient-specific vaccination plus granulocytemonocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5: 1171-7.
  • Osterborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in Myeloma patients induced typel, major histocompatibility complexrestricted, Cd8- and Cd4-specific T cell responses. Blood 1998; 91: 2549.
  • Wen YJ, Ling M, Bailey-Wood R, Lim SH. Idiotype protein pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 1998; 4:957.
  • Dabadghao S, Bergenbrant S, Anton D, He W, Holm G, Yi Q. Antiidiotypic T cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haematol 1998; 100: 647-54.
  • Reichardt VL, Okada CY, Liso A, et al Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood 1999; 93: 2411-9.
  • Nestle FO, Alijagic S, Gilliet M, et al Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32.
  • Thurner B, Haendle I, Roder C, et al Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. / Exp Med 1999; 190: 1669-78.
  • Fujii S, Shimizu K, Fujimoto K, et al. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res 1999; 90: 1117-29.
  • Panelli MC, Wunderlich J, Jeffries J, et al Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 2000; 23: 487-98.
  • Rieser C, Ramoner R, Holtl L, et al Mature dendritic cells induce T-helper type-!-dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int 2000; 63: 151-9.
  • Holtl L, Rieser C, Papesh C, et al Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999; 161: 777-82.
  • Thurnher M, Rieser C, Holtl L, Papesh C, Ramoner R, Bartsch G. Dendritic cell-based immunotherapy of renal cell carcinoma. Urol Int 1998; 61: 67-71.
  • Kugler A, Stuhler G, Waiden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000; 6: 332-6.
  • Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201 -specific peptides from prostatespecific membrane antigen. Prostate 1996; 29: 371-80.
  • Murphy GP, Tjoa BA, Simmons SJ, et al Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999; 39: 54-9.
  • Murphy GP, Tjoa BA, Simmons SJ, et al Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase 2 prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999; 38: 73-8.
  • Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000; 60: 829-33.
  • Murphy GP, Snow P, Simmons SJ, et al Use of artificial neural networks in evaluating prognostic factors determining the response to dendritic cells pulsed with PSMA peptides in prostate cancer patients. Prostate 2000; 42: 67-72.
  • Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormonerefractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894-903.
  • Tjoa BA, Murphy GP. Development of dendritic-cell based prostate cancer vaccine, lmmunol Lett 2000; 74: 87-93.
  • Tjoa BA, Simmons SJ, Bowes VA, et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998; 36: 39-44.
  • Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 1999; 40: 125-9.
  • Salgaller ML, Lodge PA, McLean JG, et al Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HlA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 1998; 35: 144-51.
  • Nair SK, Hull S, Coleman D, Gilboa E, Lyerly HK, Morse MA. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int J Cancer 1999; 82: 121-4.
  • Morse M, Deng Y, Coleman D, et al A phase 1 study of active immunotherapy with carcinoembryonic antigen peptide (CAPD-pulsed, autologous human cultured dendritic cells in patients with metastatic cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999; 5: 1331-8.
  • Brossait P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96: 3102-8.
  • Geiger J, Hutchinson R, Hohenkirk L, McKenna E, Chang A, Mule J. Treatment of solid tumours in children with tumour-lysate-pulsed dendritic cells. (Letter.) Lancet 2000; 356: 1163-5.
  • Cao H, Verge V, Baron C, et al. In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy. J Hematother Stem Cell Res 2000; 9: 183-94.
  • Mortarini R, Anichini A, Di Nicola M, et al Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 1997; 57: 5534-41.
  • Toujas L, Delcros JG, Diez E, et al. Human monocyte-derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I-restricted exogenous peptides. Immunology 1997; 91: 635-42.
  • Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SM. Optimization of the sequence of antigen loading and CD40-ligand induced maturation of dendritic cells. Cancer Research 1998; 58: 2965-8.
  • Nestle F, Banchereau J, Hart DNJ. Dendritic cells: on the move from the bench to the bedside. Nat Med 2001; 7: 761.
  • Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 281-7.
  • Toes RE, van der Voort EI, Schoenberger SP, et al. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J lmmunol 1998; 160: 4449-56.
  • Mannering SI, McKenzie JL, Fearnley DB, Hart DNJ. HLA-DR beta*1010 presents bcr-abl (b3a2) peptide to CD4+ T lymphocytes: optimal presentation by blood dendritic cells. Blood 1997; 90: 290-7.
  • Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60: 1028-34.
  • Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999; 10: 673-9.
  • Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 1999; 59: 56-8.
  • Eggert A, Schreurs M, Boerman O, et al Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999; 59: 3340-5.
  • Serody JS, Collins EJ, Tisch RM, Kuhns JJ, Frelinger JA. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J Immunol 2000; 164: 4961-7.
  • Pong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. JImmunol 2001; 166: 4254-9.
  • Steinbrink K, Jonuleit H, Muller G, Schuler G, Knop J, Enk AH. Interleukin-10 treated human dendritic cells induce a melanoma antigen-specific anergy in CDS + T cells resulting in a failure to lyse tumor cells. Blood 1999; 93: 1634-2.
  • Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer Immunol Immunother 2000; 49: 152-6.
  • McGuckin MA, MacDonald KPA, Tran M, Wykes M, Hart DNJ. MUCI epithelial mucin-expression by normal haematopoietic cells. In: Mason D, ed. Leucocyte Typing VII. Oxford: Oxford University Press (in press).
  • Bellone M, Cantarella D, Castiglioni P, et al Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J lmmunol 2000; 165: 2651-6.
  • Zeh HI, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J lmmunol 1999; 162: 989-94.
  • Molldrem JJ, Lee PP, Wang C, et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018-23.
  • Panelli MC, Riker A, Kammula U, et al Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J lmmunol 2000; 164: 495-504.
  • Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.
  • Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv lmmunol 2000; 74: 181-73.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.